|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).
|
9652611 |
1998 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with BRCA1- or BRCA2-associated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and therefore may consider secondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy.
|
10665701 |
2000 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 mutation carriers had a significantly earlier age of diagnosis than non-carriers (p = 0.0001) and more frequently developed contralateral breast cancer (p = 0.04).
|
10817354 |
2000 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We studied the contralateral breast cancer risk in 164 patients from 83 families with a proven BRCA1 mutation in relation to the age at diagnosis of the first primary breast cancer.
|
10917555 |
2000 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tamoxifen protected against contralateral breast cancer for carriers of BRCA1 mutations (odds ratio 0.38, 95% CI 0.19-0.74) and for those with BRCA2 mutations (0.63, 0.20-1.50).
|
11130383 |
2000 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the BRCA1 or BRCA2 genes have been shown to strongly predispose towards the development of contralateral breast cancer in patients from large multi-case families.
|
11556836 |
2001 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
|
15197194 |
2004 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1/2 mutation carriers diagnosed with breast cancer have a strong life time risk of developing contralateral breast cancer (53% versus 2%).
|
15319244 |
2004 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of BRCA1 and BRCA2 mutations have an increased risk of contralateral breast cancer and cancer of the ovary.
|
15952973 |
2005 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data show that CPM markedly reduces the risk of contralateral breast cancer among BRCA1 or BRCA2 mutation carriers with a history of breast cancer.
|
16052221 |
2005 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Women with BRCA1 or BRCA2 mutations should be informed about the increased risk of contralateral breast cancer and ipsilateral failure after breast-conservation therapy.
|
16111473 |
2005 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rate of contralateral breast cancer was significantly increased in all patients with a family history: BRCA1/2 carriers versus controls (p=0.0003), non-carriers versus controls (p=0.0034) and carriers versus non-carriers (p=0.02).
|
16140006 |
2005 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
At multivariate analysis CBC incidence was increased in late-tested non-BRCA1/2 (HR 4.6; p = 0.001) not in 'unselected' (HR 1.8; p = 0.1).
|
16319990 |
2006 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 for carriers of BRCA1 mutations (95% CI, 0.30-0.85) and was 0.42 for carriers of BRCA2 mutations (95% CI, 0.17-1.02).
|
16331614 |
2006 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumour size (hazard ratio (HR) 1.02 per mm increase, P = 0.016) and node status (HR 2.6 for three or more involved nodes versus node negative, P = 0.017) were independent predictors of overall survival in the familial non-BRCA1/2 group, and in the whole group, whereas contralateral breast cancer (HR 0.7, P = 0.503) and risk-reducing contralateral mastectomy (HR 0.4, P = 0.163) were not.
|
16758466 |
2006 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent studies indicate that high-risk breast cancer patients (ie, women who carry mutations in BRCA1/2 genes) who opt for contralateral prophylactic mastectomy (CPM) have a substantially reduced risk of developing contralateral breast cancer.
|
17159191 |
2007 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Participants previously diagnosed with contralateral breast cancer or unilateral breast cancer were genotyped for mutations in BRCA1 and BRCA2.
|
18182601 |
2008 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This may explain the effectiveness of tamoxifen in preventing contralateral breast cancer development in BRCA1 mutation carriers.
|
18405391 |
2008 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Preclinical and clinical data reveal that at highest risk of IBC/CBC are patients with inherited BRCA1/2 mutations who benefited from bilateral mastectomy.
|
19322611 |
2009 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
|
19597986 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After 25 years, 62.9% (95% CI, 50.4% to 75.4%) of patients with BRCA1 mutation who were younger than 40 years of age at first breast cancer developed contralateral breast cancer, compared with only 19.6% (95% CI, 5.3% to 33.9%) of those who were older than 50 years of age at first breast cancer.
|
19858402 |
2009 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the association between these factors and CBC risk among BRCA1 and BRCA2 (BRCA1/2) mutation carriers and non-carriers.
|
20130978 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conditional logistic regression was used to compare the risk of CBC associated with chemotherapy and tamoxifen in BRCA1/BRCA2 mutation carriers and non-carriers.
|
20135344 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 10-year risk for contralateral breast cancer was 34.2% (29.4-39.0%) in BRCA1 families and 29.2% (22.9-35.5%) in BRCA2.
|
20204502 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The relative risk of contralateral breast cancer for BRCA1 mutation carriers increased as age of first diagnosis decreased.
|
20368571 |
2010 |